Skip to content

Carfilzomib

An FDA-approved second-generation, irreversible epoxyketone proteasome inhibitor — derived from the natural product epoxomicin — used intravenously in relapsed and refractory multiple myeloma.

StrongModerate Data
Last updated 12 citations

What is Carfilzomib?

Carfilzomib is a synthetic tetrapeptide epoxyketone that irreversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Structurally derived from the microbial natural product epoxomicin, it was developed by Proteolix (later acquired by Onyx Pharmaceuticals, then Amgen) as a second-generation proteasome inhibitor designed to overcome the dose-limiting peripheral neuropathy and acquired resistance seen with the first-in-class peptide-boronate bortezomib. Carfilzomib received accelerated FDA approval in July 2012 as monotherapy for relapsed and refractory multiple myeloma based on the PX-171-003-A1 single-arm Phase 2 trial, with full approval and combination indications following on the strength of the ASPIRE (KRd) and ENDEAVOR (Kd vs Vd) Phase 3 trials. It is administered exclusively by intravenous infusion in an oncology infusion-center setting and has no use outside of supervised cancer care.

What Carfilzomib Is Investigated For

Carfilzomib is an FDA-approved proteasome inhibitor whose clinical home is relapsed and refractory multiple myeloma. Initial accelerated approval (2012) was based on the PX-171-003-A1 Phase 2 trial in heavily pretreated patients who had received at least two prior therapies including bortezomib and an immunomodulatory drug, where single-agent carfilzomib produced a 23.7% overall response rate. Full approval came on the strength of two Phase 3 trials: ASPIRE (Stewart et al., NEJM 2015) randomized 792 relapsed-myeloma patients to carfilzomib + lenalidomide + dexamethasone (KRd) versus Rd alone and showed a 26.3- vs 17.6-month progression-free survival benefit, with an overall survival benefit confirmed in the 2018 final analysis (Siegel et al., JCO 2018); and ENDEAVOR (Dimopoulos et al., Lancet Oncology 2016) was the first Phase 3 head-to-head between two proteasome inhibitors, comparing carfilzomib + dexamethasone (Kd) at 56 mg/m² with bortezomib + dexamethasone (Vd) and showing roughly doubled PFS (18.7 vs 9.4 months) and improved OS in the 2017 interim analysis. The signal in relapsed myeloma is robust and consistent. The honest counterweights are real and important: cardiovascular toxicity is the defining safety concern — a Waxman et al. JAMA Oncology 2018 meta-analysis reported high-grade cardiovascular adverse events (heart failure, hypertension, ischemia, arrhythmia) in roughly 8–18% of carfilzomib-treated patients, materially higher than with bortezomib; infusion reactions, acute kidney injury, thrombotic microangiopathy, and pulmonary toxicity are all on the label. Carfilzomib is also an IV-only drug, making logistics burdensome compared with subcutaneous bortezomib or oral ixazomib. Front-line attempts have been less successful: the CLARION Phase 3 trial (Facon et al., Blood 2019) of KMP versus VMP in transplant-ineligible newly-diagnosed myeloma did not show superiority for the carfilzomib arm and produced more cardiac and renal events, so carfilzomib is not standard front-line therapy. Its role is as a high-potency relapsed-disease drug — particularly valuable in bortezomib-refractory patients and in fit patients who can tolerate the cardiovascular monitoring burden.

Relapsed and refractory multiple myeloma (monotherapy and in combination)
Strong90%
Relapsed multiple myeloma in combination with lenalidomide and dexamethasone (KRd, ASPIRE regimen)
Strong90%
Relapsed multiple myeloma in combination with dexamethasone (Kd, ENDEAVOR regimen)
Strong90%
Relapsed multiple myeloma with daratumumab combinations (DKd)
Moderate70%
Front-line multiple myeloma (CLARION trial was negative; not standard front-line)
Limited15%

History & Discovery

Carfilzomib's lineage starts not in a pharmaceutical lab but in a microbial fermentation broth. In 1992, researchers in Japan reported epoxomicin, a linear tetrapeptide α',β'-epoxyketone natural product isolated from an Actinomycetes strain that showed striking antitumor activity in murine melanoma models, with no protein target identified at the time. In 1999, Craig Crews and colleagues at Yale University reported in Proceedings of the National Academy of Sciences that epoxomicin's target was the 20S proteasome's chymotrypsin-like β5 active site, and that the unusual α',β'-epoxyketone warhead formed a covalent morpholino-ring adduct with the proteasomal N-terminal threonine — a binding mode that explained the natural product's specificity for the proteasome over other proteases. This identification opened a rational drug-design path. Crews co-founded Proteolix in 2003 to develop synthetic peptidyl epoxyketones as therapeutic proteasome inhibitors. The lead compound, designated PR-171, was a four-amino-acid peptide capped with the epoxomicin-style epoxyketone warhead, designed to be more potent and more β5-selective than bortezomib while retaining the tractable synthetic chemistry needed for a drug. Demo et al. published the foundational preclinical characterization in Cancer Research in 2007, showing irreversible β5 inhibition, broad anti-tumor activity in hematologic malignancy cell lines, and — critically — activity in bortezomib-resistant models. The drug entered Phase 1 trials in 2005 and progressed rapidly into the relapsed-myeloma Phase 2 program. Proteolix was acquired by Onyx Pharmaceuticals in 2009 for approximately $851 million, with the carfilzomib program as the centerpiece. Onyx ran the pivotal PX-171-003-A1 Phase 2 trial (Siegel et al., Blood 2012) in heavily pretreated relapsed and refractory myeloma patients who had exhausted bortezomib and IMiDs; the 23.7% overall response rate in this population was the basis for FDA accelerated approval on July 20, 2012, under the brand name Kyprolis. Amgen acquired Onyx in 2013 for $10.4 billion, primarily for carfilzomib. Full FDA approval and label expansion came on the strength of the ASPIRE Phase 3 trial (Stewart et al., NEJM 2015) of KRd vs Rd, which showed a 26.3- vs 17.6-month progression-free survival benefit and was the basis for the 2015 KRd combination approval, and the ENDEAVOR trial (Dimopoulos et al., Lancet Oncology 2016) of Kd vs Vd, which was the first Phase 3 head-to-head between two proteasome inhibitors and showed roughly doubled PFS for carfilzomib at the 56 mg/m² dose. Once-weekly dosing at 70 mg/m² was approved on the basis of the ARROW trial in 2018. Front-line attempts have been less successful: the CLARION Phase 3 trial (Facon et al., Blood 2019) of KMP vs VMP in transplant-ineligible newly-diagnosed myeloma was negative, and the ENDURANCE trial of KRd vs VRd in standard-risk newly-diagnosed myeloma also failed to show superiority. Carfilzomib's settled clinical home is the relapsed and refractory setting, where its irreversible binding offers genuine activity in bortezomib-pretreated disease at the cost of a more demanding cardiovascular monitoring profile.

How It Works

The proteasome is the cell's protein shredder — a barrel-shaped complex that grinds up misfolded or no-longer-needed proteins back into amino acids. Carfilzomib jams that shredder by sticking to it irreversibly. Plasma cells (and the malignant myeloma cells that come from them) churn out enormous amounts of antibody protein and have to depend on the proteasome to clear the misfolded byproducts; when the shredder gets jammed, the misfolded protein piles up to lethal levels and the cell dies. Carfilzomib's irreversible binding means the cell can only recover by building entirely new proteasomes, which takes time and produces deeper, more sustained inhibition than the reversible binding of bortezomib.

Carfilzomib is a synthetic tetrapeptide epoxyketone modeled on the natural product epoxomicin (originally isolated from an Actinomycetes strain in the 1990s). The C-terminal α',β'-epoxyketone warhead reacts with the N-terminal threonine (Thr1) of the proteasome's β5 chymotrypsin-like catalytic subunit, forming a covalent six-membered morpholino-ring adduct via dual reaction with the threonine hydroxyl and amine. This bond is functionally irreversible — proteasome activity recovers only as new proteasome subunits are synthesized — and produces deeper and more sustained chymotrypsin-like inhibition than the reversible boronate of bortezomib. The peptidyl epoxyketone scaffold also provides high specificity for the proteasome over other serine and cysteine proteases, because the morpholino-ring chemistry depends on the unusual N-terminal threonine that is unique to the proteasome's catalytic subunits. Downstream, the consequences are similar to bortezomib but more sustained: stabilization of IκBα suppresses NF-κB signaling and removes a survival input the myeloma microenvironment depends on; accumulation of polyubiquitinated misfolded immunoglobulin in plasma-lineage cells triggers a terminal unfolded protein response and ER-stress-mediated apoptosis; pro-apoptotic regulators (NOXA, BIM, p53) and cell-cycle inhibitors (p21, p27) are stabilized. The Demo et al. (Cancer Research, 2007) preclinical paper demonstrated that PR-171's irreversible binding produced apoptosis even in bortezomib-resistant myeloma cell lines and primary patient samples, providing the mechanistic rationale for clinical activity in bortezomib-refractory disease. The lower peripheral-neuropathy signal versus bortezomib is attributed to less off-target inhibition of the HtrA2/Omi serine protease and other neuronal proteases that bortezomib's boronate warhead engages — though the cardiovascular signal that emerged in clinical use was not predicted by preclinical work and remains incompletely understood at a mechanistic level.

Evidence Snapshot

Overall Confidence92%

Human Clinical Evidence

Extensive in relapsed/refractory multiple myeloma. Pivotal Phase 2 (PX-171-003-A1, PX-171-004) and Phase 3 (ASPIRE, ENDEAVOR, CLARION) trials, plus a decade of real-world post-approval use. Front-line evidence is mixed and carfilzomib is not standard front-line.

Animal / Preclinical

Comprehensive. Demo et al. (2007) established PR-171 as an irreversible β5-selective epoxyketone with broad anti-myeloma activity including in bortezomib-resistant models.

Mechanistic Rationale

Very strong. The covalent epoxyketone-threonine adduct is structurally and biochemically defined, and plasma-cell UPR / NF-κB dependence is the same mechanism that drives bortezomib's clinical effect.

Research Gaps & Open Questions

What the current literature has not yet settled about Carfilzomib:

  • 01Mechanism of cardiovascular toxicity — the precise molecular basis for carfilzomib-associated heart failure, hypertension, and ischemia is not resolved; competing hypotheses include direct cardiomyocyte proteasome inhibition, endothelial nitric-oxide dysregulation, and acute afterload effects, but no unifying model has emerged.
  • 02Predictors of cardiovascular events — baseline clinical, biomarker (NT-proBNP, troponin), or imaging predictors that reliably identify patients at high risk for severe cardiovascular events on carfilzomib are not established; optimal monitoring intensity is not standardized.
  • 03Optimal sequencing in modern multi-line myeloma pathways — the relative role of carfilzomib versus daratumumab-, BCMA-, and bispecific-antibody-based regimens, and the question of whether bortezomib- vs carfilzomib-based induction better preserves later-line options, remains unsettled.
  • 04Front-line role — multiple Phase 3 front-line trials (CLARION, ENDURANCE) have failed to show superiority over bortezomib-based regimens; whether there is a defined front-line niche for carfilzomib (e.g., in high-risk cytogenetic subgroups) is an open question.
  • 05Mechanisms of acquired resistance — proteasome subunit mutations, drug efflux, compensatory autophagy, and altered UPR signalling all contribute, but a unified resistance framework and a strategy for re-sensitization are not yet established.
  • 06Once-weekly higher-dose schedules — the long-term safety and durability of the 70 mg/m² once-weekly schedule (ARROW) compared with twice-weekly schedules in the post-daratumumab era continues to be characterized.

Forms & Administration

Intravenous infusion only. Standard schedules: in the ASPIRE regimen (KRd), carfilzomib 27 mg/m² over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle (with a 20 mg/m² lead-in dose on cycle 1 days 1–2); in the ENDEAVOR regimen (Kd), carfilzomib 56 mg/m² over 30 minutes on the same days (also with a 20 mg/m² lead-in); a 70 mg/m² once-weekly schedule (ARROW trial) is also approved. Dexamethasone premedication (typically 4–8 mg) is given before each carfilzomib dose during cycle 1 and as needed thereafter to prevent infusion reactions. Pre-infusion hydration (250–500 mL of intravenous fluid) is standard during cycle 1 to mitigate tumor lysis and acute kidney injury. Carfilzomib is dispensed and administered only by qualified oncology providers in an infusion-center or hospital setting; it is not self-administered and has no oral, subcutaneous, or at-home formulation.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

20 to 70 mg/m² body surface area per dose, with a step-up from a 20 mg/m² lead-in on cycle 1 days 1–2 to the target dose from cycle 1 day 8 onward. Standard targets are 27 mg/m² in the ASPIRE KRd regimen (twice-weekly), 56 mg/m² in the ENDEAVOR Kd regimen (twice-weekly), or 70 mg/m² once-weekly per the ARROW schedule. Dose reductions to one dose level lower (typically 20 → 15 → 11 mg/m² or 56 → 45 → 36 mg/m²) are standard for cardiac, renal, hepatic, or hematologic toxicity per the label algorithm.

Frequency

Intravenous infusion only. Twice-weekly schedules: days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Once-weekly schedule: days 1, 8, and 15 of each 28-day cycle. Infusion duration is 10 minutes for the 27 mg/m² dose and 30 minutes for the 56 mg/m² and 70 mg/m² doses. Dexamethasone premedication is given before each dose during cycle 1 and as needed thereafter to mitigate infusion reactions. Pre- and post-infusion intravenous hydration (250–500 mL) is standard during cycle 1 to reduce the risk of tumor lysis and acute kidney injury.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

28-day cycles, typically continued until disease progression or unacceptable toxicity. In the KRd regimen, carfilzomib is generally given for 18 cycles in trial protocols; lenalidomide and dexamethasone may continue beyond that. In the Kd regimen, carfilzomib is continued until progression or toxicity. Total treatment duration is individualized based on response, tolerability, and the specific combination regimen.

Protocol Notes

Carfilzomib is almost always given in combination rather than as monotherapy in modern relapsed-myeloma practice. The two anchor regimens are KRd (carfilzomib + lenalidomide + dexamethasone, the ASPIRE regimen) and Kd (carfilzomib + dexamethasone, the ENDEAVOR regimen, typically at 56 mg/m² twice-weekly or 70 mg/m² weekly). Daratumumab-containing triplets (DKd, isatuximab-Kd) are also approved in the relapsed setting based on the CANDOR and IKEMA trials respectively. Cardiovascular monitoring is the single most important ongoing management task. Baseline blood pressure should be optimized before starting therapy, with a low threshold for adding antihypertensives during therapy. Baseline echocardiography and natriuretic peptide (BNP or NT-proBNP) measurement are appropriate in patients with pre-existing cardiac disease, older age, prior anthracycline exposure, or amyloid involvement. Any new dyspnea, chest pain, orthopnea, or peripheral edema during therapy should trigger prompt cardiac evaluation and consideration of dose hold or reduction. The Waxman et al. JAMA Oncology 2018 meta-analysis quantified the all-grade cardiovascular event rate at roughly 18% and grade 3+ rate at roughly 8% across pooled trials, so this is a real and frequent concern, not a theoretical one. Infusion reactions are most common with the first dose; dexamethasone premedication and a slower initial infusion rate substantially reduce the rate. Hydration before and after infusion during cycle 1 reduces tumor lysis syndrome and acute kidney injury risk in patients with bulky disease. Antiviral prophylaxis (acyclovir or valacyclovir) is standard to prevent herpes zoster reactivation. Pneumocystis prophylaxis may be appropriate depending on the combination regimen and lymphocyte count. Renal dose adjustment is described in the label, although clearance of carfilzomib itself is largely non-renal — the dose adjustments primarily reflect tolerability rather than altered exposure.

Carfilzomib is an FDA-approved oncology drug for relapsed and refractory multiple myeloma. It must be prescribed and administered only by an oncologist or hematologist in an appropriate supervised infusion-center or hospital setting, as part of a defined treatment protocol. It is not a peptide for self-administration and has no role in wellness, performance, or anti-aging use. Cardiovascular monitoring and dose-modification thresholds in the prescribing label must be followed strictly.

Timeline of Effects

Onset

Proteasome chymotrypsin-like activity is suppressed by greater than 80% within 1 hour of the first carfilzomib dose, with sustained inhibition over the dosing interval because of the drug's irreversible binding. Recovery of proteasome activity depends on de novo subunit synthesis and typically takes 48–72 hours. Clinical tumor response — decline in serum or urine monoclonal protein in myeloma — typically emerges over the first 2–4 cycles (approximately 2–4 months).

Peak Effect

In ASPIRE, maximal response with KRd was reached over cycles 4–8, with median time to response of 1.6 months and ongoing depth-of-response improvement (VGPR, near-CR, CR) accumulating through cycle 12. In ENDEAVOR, Kd produced an overall response rate of 77% with a median PFS of 18.7 months. Continuation of therapy beyond initial response generally maintains rather than substantially deepens the response, with treatment continued until progression or toxicity.

After Discontinuation

Proteasome activity recovers over days as new proteasome subunits are synthesized. The anti-tumor effect of a completed course persists for months depending on disease biology, prior therapies, and use of maintenance regimens; in the relapsed setting, time to next therapy after carfilzomib-based induction is typically measured in months to a couple of years. Cardiovascular events that emerge during therapy — particularly heart failure and hypertension — are often partially reversible with discontinuation and standard cardiac care, but pre-existing damage may persist. Herpes zoster risk declines after treatment completion but antiviral prophylaxis is typically continued for a period after the final dose.

Common Questions

Who Carfilzomib Is NOT For

Contraindications
  • •Known hypersensitivity to carfilzomib or formulation excipients (cyclodextrin-based vehicle).
  • •Pregnancy — carfilzomib is embryotoxic and fetotoxic in animal studies; pregnancy must be excluded before treatment and effective contraception is required during and for a defined interval after therapy in both female patients and female partners of male patients.
  • •Breastfeeding — not recommended during carfilzomib therapy.
  • •Active or recent severe cardiac disease (heart failure, recent myocardial infarction, unstable angina, uncontrolled arrhythmia) — relative contraindication; if treatment is still indicated, dose reduction, intensified cardiac monitoring, and cardiology co-management are required.
  • •Uncontrolled hypertension — must be optimized before starting therapy.
  • •Amyloid cardiomyopathy — relative contraindication given high baseline cardiac vulnerability.
  • •Active pulmonary hypertension or significant pulmonary disease — relative contraindication; risk of worsening on therapy.
  • •Severe hepatic impairment — dose reduction is required and use is cautious.
  • •Acute infection — therapy should generally be deferred until the infection is controlled.

Drug & Supplement Interactions

Carfilzomib is metabolized predominantly via peptidase cleavage and epoxide hydrolysis rather than CYP-mediated oxidation, so classical CYP3A4 drug-drug interactions are limited compared with bortezomib. Dedicated drug-interaction studies have not shown clinically meaningful exposure changes with strong CYP3A inhibitors or inducers, and carfilzomib does not appreciably inhibit or induce major CYP enzymes. Pharmacodynamic interactions are more clinically important than pharmacokinetic ones. The most important pharmacodynamic concerns relate to cardiovascular and renal effects. Concomitant use with anthracyclines, trastuzumab, or other cardiotoxic agents may compound cardiac risk; many guidelines recommend particular caution and intensified monitoring in patients with prior anthracycline exposure. Concomitant use with nephrotoxic agents (NSAIDs, aminoglycosides, IV contrast, calcineurin inhibitors) increases acute-kidney-injury risk and should be minimized during carfilzomib therapy. Lenalidomide and high-dose dexamethasone are common combination partners (the KRd regimen) and add their own thrombosis and infection risks; thromboprophylaxis (aspirin, low-molecular-weight heparin, or DOACs depending on risk) is standard with the KRd regimen. Herpes zoster prophylaxis with low-dose acyclovir (typically 400 mg daily) or valacyclovir is standard during carfilzomib therapy. Live vaccines (varicella, zoster-live, yellow fever, MMR) should not be administered during or shortly after carfilzomib because of treatment-related immunosuppression; inactivated and recombinant vaccines are safe but immune response may be attenuated. Hormonal contraceptives may not be reliable in the setting of vomiting or significant GI toxicity; backup contraception is appropriate. As with any oncology specialty drug, all prescription, over-the-counter, and supplement use should be disclosed to the oncology team.

Safety Profile

Safety Information

Common Side Effects

Cardiovascular events — hypertension, heart failure, ischemia, arrhythmia, pulmonary hypertension (the defining safety signal)Infusion reactions — fever, chills, dyspnea, hypotension, chest tightness (usually within 24 hours of dose; mitigated by dexamethasone premedication)Fatigue and astheniaAnemia, thrombocytopenia, lymphopeniaAcute kidney injury and elevated creatinineDyspnea and respiratory effectsDiarrhea, nausea, and other GI effectsHerpes zoster reactivation (without antiviral prophylaxis)

Cautions

  • • Pre-existing cardiac disease, heart failure, recent myocardial infarction, or uncontrolled hypertension — high risk of severe cardiovascular events
  • • Amyloid cardiomyopathy — relative contraindication
  • • Older age and prior anthracycline exposure increase cardiovascular risk
  • • Pulmonary hypertension — reported and may worsen on therapy
  • • Renal impairment — dose adjustment based on creatinine clearance; monitor closely
  • • Tumor lysis syndrome — risk in high-burden disease; prophylaxis with hydration and uric-acid-lowering therapy is standard for cycle 1
  • • Thrombotic microangiopathy and posterior reversible encephalopathy syndrome (PRES) — rare but reported; require immediate discontinuation if suspected
  • • Hepatic impairment — dose reduction required in moderate-to-severe impairment
  • • Pregnancy — embryotoxic in animal studies; effective contraception required
  • • Must be administered only by an oncologist or hematologist in an appropriately staffed infusion-center setting

What We Don't Know

The precise mechanism of carfilzomib-associated cardiovascular toxicity is not fully resolved, and pre-treatment predictors of which patients will develop severe events are not well defined; optimal cardiac monitoring intensity is not standardized.

Myths & Misconceptions

Myth

Carfilzomib is just a 'better bortezomib.'

Reality

It is more accurate to call it a different proteasome inhibitor with a different trade-off profile. Carfilzomib offers irreversible β5 binding, less peripheral neuropathy, and superior PFS and OS versus bortezomib at the 56 mg/m² dose in the ENDEAVOR trial — but materially more cardiovascular toxicity, IV-only administration, and substantially higher cost. Bortezomib remains the global workhorse, particularly subcutaneously and weekly. Choosing between them is a clinical judgment based on disease status, prior exposure, comorbidities, and access — not a simple upgrade decision.

Myth

Because carfilzomib is irreversible, it has no neuropathy at all.

Reality

Carfilzomib has substantially less peripheral neuropathy than bortezomib — that was the explicit design goal — but not zero. The difference is attributed to less off-target inhibition of neuronal proteases that bortezomib's boronate engages, not to the irreversibility itself. In clinical trials carfilzomib-treated patients had peripheral neuropathy rates roughly half to a third of bortezomib-treated patients in head-to-head settings, and pre-existing neuropathy is far less of a barrier to carfilzomib use.

Myth

Carfilzomib should be used front-line in every newly diagnosed myeloma patient because it is more potent than bortezomib.

Reality

Front-line trials have not borne this out. The CLARION Phase 3 trial of KMP versus VMP in transplant-ineligible newly-diagnosed myeloma was negative, with no PFS superiority and more cardiac and renal events on the carfilzomib arm. The ENDURANCE trial of KRd versus VRd in standard-risk newly-diagnosed myeloma also failed to show superiority. Carfilzomib's clinical home is the relapsed and refractory setting, where its irreversible binding earns its keep against bortezomib-pretreated disease.

Myth

The cardiovascular risk with carfilzomib is overstated and not really a clinical issue.

Reality

The signal is real, frequent, and well quantified. The Waxman et al. JAMA Oncology 2018 meta-analysis of 24 trials with 2,594 patients reported all-grade cardiovascular adverse events in roughly 18% and grade 3+ events in roughly 8%, with heart failure and hypertension the most common. The FDA label carries warnings for cardiac toxicity, hypertension, and acute renal failure. Pre-treatment optimization of blood pressure and cardiac status, baseline assessment in higher-risk patients, and prompt evaluation of new cardiopulmonary symptoms during therapy are not optional parts of carfilzomib management.

Myth

Carfilzomib is a wellness peptide because it is described as a 'tetrapeptide.'

Reality

Carfilzomib is a prescription-only intravenous oncology drug for multiple myeloma, administered exclusively in supervised infusion-center settings under oncologist or hematologist care. It is structurally a synthetic tetrapeptide epoxyketone, but that taxonomic detail has no bearing on its clinical use. It has no role in wellness, performance, recovery, or anti-aging contexts, and no legitimate indication outside of cancer care. Any source promoting carfilzomib outside of oncology is dangerous and incorrect.

Published Research

12 studies

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Phase III Clinical TrialPMID: 30819926

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Phase III Clinical TrialPMID: 29341834

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

The Waxman et al. (JAMA Oncology, 2018) systematic review and meta-analysis of 24 prospective trials with 2,594 patients that quantified carfilzomib's cardiovascular toxicity signal. Reported all-grade cardiovascular adverse events in 18.1% of patients and grade 3+ events in 8.2%, with heart failure, hypertension, and ischemia the most common. The defining safety paper for the drug and the basis for cardiovascular monitoring guidance in the carfilzomib label.

Meta-AnalysisPMID: 29285538

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Phase III Clinical TrialPMID: 28843768

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Phase III Clinical TrialPMID: 26671818

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

The Stewart et al. ASPIRE trial (NEJM, 2015) — the Phase 3 study in 792 relapsed-myeloma patients comparing KRd (carfilzomib + lenalidomide + dexamethasone) with Rd. KRd extended progression-free survival from 17.6 to 26.3 months and improved overall response (87% vs 67%) and depth of response. ASPIRE was the basis for FDA full approval of the KRd combination and remains the foundational trial for carfilzomib in relapsed disease.

Phase III Clinical TrialPMID: 25482145

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes.

ReviewPMID: 23575525

Carfilzomib.

ReviewPMID: 23393020

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Clinical PharmacologyPMID: 23364621

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

The Siegel et al. PX-171-003-A1 trial (Blood, 2012) — the pivotal single-arm Phase 2 study in 266 heavily pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies including bortezomib and an IMiD. Single-agent carfilzomib produced a 23.7% overall response rate with a median duration of response of 7.8 months. PX-171-003-A1 was the basis for FDA accelerated approval in July 2012.

Phase II Clinical TrialPMID: 22833546

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Phase II Clinical TrialPMID: 22555973

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

The Demo et al. (Cancer Research, 2007) foundational preclinical paper that introduced PR-171 (later carfilzomib) as a tetrapeptide epoxyketone with irreversible, selective β5 chymotrypsin-like proteasome inhibition. Demonstrated anti-tumor activity across hematologic malignancy cell lines, including in bortezomib-resistant models, and provided the mechanistic and pharmacologic rationale for the entire clinical program. Seminal paper for the second-generation epoxyketone proteasome-inhibitor class.

PreclinicalPMID: 17616698

Quick Facts

Class
Proteasome Inhibitor / Peptide Epoxyketone
Evidence
Strong
Safety
Moderate Data
Updated
Apr 2026
Citations
12PubMed

Also known as

KyprolisPR-171

Tags

FDA-ApprovedOncologyPeptide-MimeticProteasome InhibitorMultiple Myeloma

Related Goals

Longevity & Anti-Aging

Evidence Score

Overall Confidence92%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.